DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1

raised blood eosinophils (EOS)
and/or raised fraction of exhaled nitric oxide (FeNO)
who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment

Over 48,000 patients aged 12 years or older have been prescribed DUPIXENT for moderate-to-severe asthma in North America and Europe as of July 20211

More than 320,000 patients have been prescribed DUPIXENT in North America and Europe as of July 2021, across indications1

DUPIXENT can be self-injected or administrated by a caregiver via a pre-filled pen or pre-filled syringe after appropriate training by a healthcare professional (HCP)2

200 mg for severe asthma patients excluding oral corticosteroid
(OCS)-dependent patients2


 

Dosage Guide 200 mg

300 mg for OCS-dependent severe asthma patients and patients requiring DUPIXENT to control comorbid moderate-to-severe atopic dermatitis (AD) or severe Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)2

Dosage Guide 300 mg

Introducing the DUPIXENT pre-filled pen

DUPIXENT pre-filled pen can be used to ensure
patients administer DUPIXENT as directed2

DUPIXENT can be administered with a pre-filled pen or pre-filled syringe2

Learn how to administer DUPIXENT using the pre-filled pen or pre-filled syringe2


How to store DUPIXENT2


 

Keep the pre-filled pen(s) or pre-filled syringe(s) and all medicines out of the reach of children

 

Keep unused pre-filled pens or pre-filled syringes in the original carton and store in the refrigerator between 2°C and 8°C

 

Store pre-filled pens or pre-filled syringes in the original carton to protect it from light

Dupixent prefilled pens and syringes

Important icon

 

Do not keep pre-filled pens or pre-filled syringes at room temperature (<25ºC) for more than 14 days2

 

Do not freeze the pre-filled pen or pre-filled syringe2

 

Do not shake the pre-filled pen or pre-filled syringe at any time2

 

Do not place the pre-filled pen or pre-filled syringe into direct sunlight2

 

Do not heat the pre-filled pen or pre-filled syringe2


Mode of action DUPIXENT


Have questions about how DUPIXENT works?




Find out more


Exacerbations and lung function

DUPIXENT can improve exacerbations and lung function of 12+ years old patients with severe asthma


Find out more


Safety profile


Learn more about the safety profile of DUPIXENT.
 

 

Find out more

    AD, atopic dermatitis; CRSwNP, Chronic Rhinosinusitis with Nasal Polyposis; HCP, healthcare professional; OCS, oral corticosteroids.

    References

    1. Sanofi Data on File. MAT-IE-2000837(v2.0). July 2021.
    2. Sanofi Genzyme. Dupixent Summary of Product Characteristics, June 2022.
    3. Dupixent Patient Information Leaflet for pre-filled pen. Available at: https://www.medicines.org.uk/emc/product/11321/pil. Date accessed: June 2022.
    4. Dupixent Patient Information Leaflet for pre-filled syringe. Available at: https://www.medicines.org.uk/emc/product/8553/pil. Date accessed: June 2022.

MAT-GB-2004975(v7.0) | Date of preparation: June 2022